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John J.V. McMurray, MDqABSTRACTOBJECTIVES The PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved
Ejection Fraction) trial is designed to determine the efﬁcacy and safety of the angiotensin receptor neprilysin inhibitor
sacubitril/valsartan compared with valsartan in patients with chronic heart failure and preserved ejection fraction
(HFpEF).
BACKGROUND HFpEF is highly prevalent, associated with substantial morbidity and mortality, and in need of effective
therapies that improve outcomes. The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan, which has
been shown to beneﬁt patients with heart failure (HF) and reduced ejection fraction, demonstrated favorable physiologic
effects in a phase II HFpEF trial.
METHODS The PARAGON-HF trial is a randomized, double-blind, parallel group, active-controlled, event-driven trial
comparing the long-term efﬁcacy and safety of valsartan and sacubitril/valsartan in patients with chronic HFpEF (left
ventricular ejection fraction $45%), New York Heart Association functional class II to IV symptoms, elevated natriuretic
peptides, and evidence of structural heart disease. Before randomization, all patients entered sequential single-blind
run-in periods to ensure tolerability of both drugs at half the target doses (i.e., valsartan titrated to 80 mg bid followed
by sacubitril/valsartan 49/51 mg [100 mg] bid). The primary outcome is the composite of cardiovascular death and total
(ﬁrst and recurrent) HF hospitalizations.
CONCLUSIONS PARAGON-HF will determine whether sacubitril/valsartan is superior to angiotensin receptor
blockade alone in patients with chronic symptomatic HFpEF. (Efﬁcacy and Safety of LCZ696 Compared to Valsartan,
on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711)
(J Am Coll Cardiol HF 2017;5:471–82) © 2017 by the American College of Cardiology Foundation.H eart failure with preserved ejection fraction(HFpEF) accounts for a large proportion ofpatients with heart failure (HF), is associ-
ated with substantial morbidity and mortality, and is
rising in prevalence as the population ages (1–3).
Several pathophysiological alterations could play a
role in HFpEF, including left ventricular hypertrophy
(LVH) and ﬁbrosis, leading to reduced chamber
compliance; impaired diastolic relaxation with resul-
tant left ventricular ﬁlling pressure elevation (4);
subtle left ventricular systolic dysfunction (5,6);
abnormalities of ventricular-vascular coupling (7);increased cardiomyocyte stiffness; and comorbidity-
induced systemic inﬂammation (8). Four outcome tri-
als using inhibitors of the renin-angiotensin-
aldosterone system (RAAS) did not meet their primary
endpoints (9–12), and currently, no therapy has
received regulatory approval to reduce morbidity and
mortality (13,14).
The ﬁrst-in-class angiotensin receptor neprilysin
inhibitor sacubitril/valsartan (formerly known as
LCZ696) simultaneously blocks the RAAS and the
endopeptidase neprilysin (15). Neprilysin is a ubiqui-
tous enzyme that is responsible for the breakdown of
ABBR EV I A T I ON S
AND ACRONYMS
ACE = angiotensin-converting
enzyme
ARB = angiotensin receptor
blocker
cGMP = cyclic guanosine
monophosphate
DMC = Data Monitoring
Committee
eGFR = estimated glomerular
ﬁltration rate
HF = heart failure
HFH = heart failure
hospitalization
HFpEF = heart failure with
preserved ejection fraction
HFrEF = heart failure with
reduced ejection fraction
KCCQ = Kansas City
Cardiomyopathy Questionnaire
LA = left atrial
LVEF = left ventricular ejection
fraction
LVH = left ventricular
hypertrophy
NP = natriuretic peptide
NT-proBNP = N-terminal
pro-brain natriuretic peptide
NYHA = New York Heart
Association
RAAS = renin-angiotensin-
aldosterone system
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logically active natriuretic peptides (NPs),
adrenomedullin, endothelin-1, and angio-
tensin. Sacubitril/valsartan is a crystalline
compound composed of both the angiotensin
receptor blocker valsartan and the neprilysin
inhibitor prodrug sacubitril that dissociates
into its component parts after ingestion.
Sacubitril is further esteriﬁed to its active
form, sacubitrilat. Sacubitril/valsartan reduced
cardiovascular and all-cause mortality, as well
as HF hospitalizations (HFHs), in patients with
HF with reduced ejection fraction (HFrEF)
compared with enalapril (16).
Patients with HFpEF can have an impaired
atrial natriuretic peptide, renal cyclic gua-
nosine monophosphate (cGMP), and natri-
uretic response to acute volume expansion
(17), as well as upregulation of phosphodies-
terase 9 in the hypertrophied cardiomyocyte,
which degrades cGMP stimulated by NPs (18).
Neprilysin inhibition augments endogenous
biologically active NPs and other vasoactive
compounds, with increased generation of
cGMP, reported to be reduced in myocardial
cells in HFpEF (19). Moreover, NP augmen-
tation induces diuresis, vasodilation, natri-
uresis, and can reduce myocardial ﬁbrosis
and improve myocardial relaxation (20). In a
phase II HFpEF trial, sacubitril/valsartan was
superior to valsartan in reducing N-terminal
pro-brain natriuretic peptide (NT-proBNP),decreasing left atrial (LA) size, and improving New
York Heart Association (NYHA) functional class (21).
These latter ﬁndings provided the rationale for an
outcomes trial in HFpEF, and here we describe the
design of the PARAGON-HF (Prospective Comparison
of ARNI With ARB Global Outcomes in Heart Failure
With Preserved Ejection Fraction) trial.
TRIAL DESIGN AND METHODS
PARAGON-HF is a randomized, double-blind, parallel
group, active-controlled, 2-arm, event-driven trial
comparing the long-term efﬁcacy and safety of
valsartan and sacubitril/valsartan in patients with
chronic symptomatic HFpEF. The trial was designed
by members of the steering committee in collabora-
tion with the sponsor. The trial has been registered
(NCT01920711).
PATIENTS. The ﬁnal eligibility criteria are summa-
rized in Table 1. Brieﬂy, patients were$50 years of age,
had a left ventricular ejection fraction (LVEF)$45% byechocardiography within the 6 months before
screening and symptoms of HF (NYHA functional class
II to IV), required diuretic therapy for at least 30 days
before screening, and had NT-proBNP >200 pg/ml if
the patient had been hospitalized for HF within the
past 9 months or >300 pg/ml without a recent HFH.
The NT-proBNP requirement was tripled if patients
were in atrial ﬁbrillation at screening. In addition,
patients had to have evidence of structural heart dis-
ease, including either LVH (i.e., septal or posterior wall
thickness $1.1 cm) or LA enlargement (i.e., width $3.8
cm, length $5.0 cm, area $20 cm2, volume $55 ml, or
volume index $29 ml/m2).
The key exclusion criteria included prior
LVEF <40% using echocardiography, an alternative
diagnosis that could account for the patient’s symp-
toms, and systolic blood pressure<110 or$180mmHg.
Patients with SBP >150 mm Hg were excluded unless
they were receiving at least 3 antihypertensive
medications at screening. Those patients with atrial
ﬁbrillation at screening were limited to approximately
33% of the study sample.
Enrollment in PARAGON-HF began on July 18,
2014, after protocol approval by the ethics commit-
tees and institutional review boards afﬁliated with
each investigative site. Patients were enrolled at 788
centers in 43 countries distributed across all major
geographic regions. The study is being conducted in
accordance with Good Clinical Practice and the
Declaration of Helsinki 2002.
STUDY DESIGN. Sequent ia l run- in per iod . The
overall study design is summarized in the Central
Illustration. After screening, in which NT-proBNP,
serum potassium, and estimated glomerular ﬁltra-
tion rate for eligibility were measured in a central
laboratory, patients entered a sequential run-in phase
in which they ﬁrst received 1 to 2 weeks of single-
blind treatment with valsartan 40 mg or 80 mg
twice daily (bid). Those started on the lower dose had
their doses up-titrated to valsartan 80 mg bid after
1 to 2 weeks. Patients who tolerated valsartan 80 mg
bid, as deﬁned by criteria in Online Table 1, were
switched to sacubitril/valsartan 49/51 mg bid (LCZ696
100 mg bid) for 2 to 4 weeks. Patients who tolerated
sacubitril/valsartan 49/51 mg bid, per criteria in
Online Table 1, were eligible for randomization. Other
background medications (except for angiotensin-
converting enzyme [ACE] inhibitors, angiotensin
receptor blockers [ARBs] and renin inhibitors) were
continued during the run-in periods.
Randomized double-blind treatment period. Patients who
tolerated both run-in periods were randomized to
TABLE 1 Eligibility Criteria
Inclusion criteria
1. Written informed consent must be obtained before any assessment is performed
2. $50 years of age, male or female
3. LVEF$45% by echocardiography during the screening epoch, or within 6 months prior to screening visit (any local LVEF measurement made using echocardiography only)
4. Symptom(s) of HF requiring treatment with diuretic(s) for at least 30 days prior to screening visit
5. Current symptom(s) of HF (NYHA functional class II to IV) at screening visit
6. Structural heart disease evidenced by at least 1 of the following echocardiography ﬁndings (any local measurement made during the screening epoch or within the
6 months prior to screening visit):
a) LA enlargement deﬁned by at least 1 of the following: LA width (diameter) $3.8 cm or LA length $5.0 cm or LA area $20 cm2 or LA volume $55 ml or LA volume
index $29 ml/m2
b) LVH deﬁned by septal thickness or posterior wall thickness $1.1 cm
7. Patients with at least 1 of the following:
a) HF hospitalization (deﬁned as HF listed as the major reason for hospitalization) within 9 months prior to screening visit and NT-proBNP >200 pg/ml for patients
not in AF or >600 pg/ml for patients in AF on screening ECG, or
b) NT-proBNP >300 pg/ml for patients not in AF or >900 pg/ml for patients in AF on the screening visit ECG
Exclusion criteria
1. Any prior echocardiographic measurement of LVEF <40%
2. Acute coronary syndrome (including MI), cardiac surgery, other major cardiovascular surgery, or urgent PCI within the 3 months prior to visit 1 or an elective PCI
within 30 days prior to visit 1
3. Any clinical event within the 6 months prior to visit 1 that could have reduced the LVEF (e.g., MI, CABG), unless an echocardiographic measurement was performed
after the event conﬁrming the LVEF to be $45%
4. Current acute decompensated HF requiring augmented therapy with diuretic agents, vasodilator agents, and/or inotropic drugs
5. Patients who require treatment with 2 or more of the following: an ACEI, an ARB, or a renin inhibitor
6. History of hypersensitivity to any of the study drugs or to drugs of similar chemical classes
7. Patients with a known history of angioedema
8. Probable alternative diagnoses that in the opinion of the investigator could account for the patient’s HF symptoms (i.e., dyspnea, fatigue), such as signiﬁcant
pulmonary disease (including primary pulmonary hypertension), anemia, or obesity. Speciﬁcally, patients with the following are excluded:
a) Severe pulmonary disease including COPD (i.e., requiring home oxygen, chronic nebulizer therapy, or chronic oral steroid therapy or hospitalized for pulmonary
decompensation within 12 months) or
b) Hemoglobin <10 g/dl, or
c) Body mass index >40 kg/m2
9. Patients with any of the following:
a) Systolic blood pressure (SBP) $180 mm Hg at visit 1, or
b) SBP >150 mm Hg and <180 mm Hg at visit 1 unless the patient is receiving 3 or more antihypertensive drugs. Antihypertensive drugs include but are not limited
to a thiazide or other diuretic, mineralocorticoid (MRA), ACEI, ARB, beta blocker, and calcium channel blocker, or
c) SBP <110 mm Hg at visit 1, or
d) SBP <100 mm Hg or symptomatic hypotension as determined by the investigator at visit 103 or visit 199/201
10. Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer
11. Patients with history of any dilated cardiomyopathy, including peripartum cardiomyopathy, chemotherapy-induced cardiomyopathy, or viral myocarditis
12. Evidence of right-sided HF in the absence of left-sided structural heart disease
13. Known pericardial constriction, genetic hypertrophic cardiomyopathy, or inﬁltrative cardiomyopathy
14. Clinically signiﬁcant congenital heart disease that could be the cause of the patient’s symptoms and signs of HF
15. Presence of hemodynamically signiﬁcant valvular heart disease in the opinion of the investigator
16. Stroke, transient ischemic attack, carotid surgery, or carotid angioplasty within the 3 months prior to visit 1
17. Coronary or carotid artery disease or valvular heart disease likely to require surgical or percutaneous intervention during the trial
18. Life-threatening or uncontrolled dysrhythmia, including symptomatic or sustained ventricular tachycardia and AF or atrial ﬂutter with a resting ventricular rate
>110 beats per minute
19. Patients with a cardiac resynchronization therapy device
20. Patients with prior major organ transplant or intent to transplant (i.e., on transplant list)
21. Any surgical or medical condition that in the opinion of the investigator may place the patient at higher risk from his/her participation in the study or is likely to
prevent the patient from complying with the requirements of the study or completing the study
22. Any surgical or medical condition that might signiﬁcantly alter the absorption, distribution, metabolism, or excretion of study drugs, including but not limited to
any of the following: any history of pancreatic injury, pancreatitis, or evidence of impaired pancreatic function/injury within the past 5 years
23. Evidence of hepatic disease as determined by any 1 of the following: SGOT (AST) or SGPT (ALT) values exceeding 3 the upper limit of normal, bilirubin >1.5 mg/dl at visit 1
24. Patients with 1 of the following:
a) eGFR <30 ml/min/1.73 m2 as calculated by the Modiﬁcation in Diet in Renal Disease (MDRD) formula at visit 1, or
b) eGFR <25 ml/min/1.73 m2 at visit 103 or visit 199/201, or
c) eGFR reduction >35% (compared with visit 1) at visit 103 or visit 199/201
25. Presence of known functionally signiﬁcant bilateral renal artery stenosis
26. Patients with either of the following:
a) Serum potassium >5.2 mmol/l (mEq/l) at visit 1
b) Serum potassium >5.4 mmol/l (mEq/l) at visit 103 or visit 199/201
27. History or presence of any other disease with a life expectancy of <3 years
28. History of noncompliance to medical regimens and patients who are considered potentially unreliable
29. History or evidence of drug or alcohol abuse within the past 12 months
30. Persons directly involved in the execution of this protocol
31. History of malignancy of any organ system (other than localized basal or squamous cell carcinoma of the skin or localized prostate cancer), treated or untreated,
within the past 5 years, regardless of whether there is evidence of local recurrence or metastases
32. Pregnant or nursing (lactating) women, where pregnancy is deﬁned as the state of a female after conception and until the termination of gestation, conﬁrmed by a
positive human chorionic gonadotropin laboratory test
33. Women of child-bearing potential, deﬁned as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of
contraception during dosing and for 7 days off study drug
ACEI ¼ angiotensin-converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ALT ¼ alanine aminotransferase; ARB ¼ angiotensin receptor blocker; AST ¼ aspartate aminotransferase; CABG ¼ coronary artery
bypass graft; COPD ¼ chronic obstructive pulmonary disease; ECG ¼ electrocardiogram; eGFR ¼ estimated glomerular ﬁltration rate; HF ¼ heart failure; LA ¼ left atrial; LVEF ¼ left ventricular ejection
fraction; LVH ¼ left ventricular hypertrophy; MI ¼ myocardial infarction; MRA ¼ mineralocorticoid receptor antagonist; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; NYHA ¼ New York Heart
Association; PCI ¼ percutaneous coronary intervention; SGOT ¼ serum glutamic-oxaloacetic transaminase; SGPT ¼ serum glutamic-pyruvic transaminase.
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CENTRAL ILLUSTRATION Study Schematic and Mechanism of Action of Sacubitril/Valsartan
Solomon, S.D. et al. J Am Coll Cardiol HF. 2017;5(7):471–82.
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477double-blind treatment with either valsartan 160 mg
bid or sacubitril/valsartan 97/103 mg bid (LCZ696
200 mg bid). In this ongoing study, study visits
occur every 4 to 16 weeks during the ﬁrst 48 weeks
and every 12 weeks thereafter. Visits are conducted
telephonically or in-person at the study site in an
alternating manner beginning at week 60 and
continuing until the end of the trial, with additional
telephonic or in-person unscheduled visits at the
discretion of the investigator. Patients are treated
with optimal diuretic regimens and other back-
ground medications (except for ACE inhibitors,
ARBs, and renin inhibitors) to effectively manage
comorbidities. Investigators are instructed to make
every effort to control patients’ blood pressure in
accordance with international and local treatment
guidelines.
Patients are asked to complete the Kansas City
Cardiomyopathy Questionnaire (KCCQ) at baseline
before the start of any study medication; at
randomization; at 16, 32, and 48 weeks after the
start of the double-blind period; and annually
thereafter. Patients are administered the Mini
Mental State Examination at randomization and
annually thereafter.
Monitor ing of safety and to lerab i l i ty dur ing
double-b l ind per iod . Patients are assessed at each
study visit for adverse events. Blood samples to
assess blood biochemistry are collected at the
screening visit and at every study visit, and samples
for hematology are collected at the screening visit;
after valsartan run-in; after sacubitril/valsartan run-
in/randomization; at 16 and 48 weeks; and annually
thereafter. Patients who do not tolerate the target
study drug dose can have the dose down-titrated at
the investigator’s discretion, with encouragement for
rechallenging these patients.
Key substud ies . An echocardiographic substudy
designed to characterize cardiac structure and
function at screening is being performed with core
laboratory assessment in approximately 1,200
patients. A biomarker substudy has been designed to
compare the effects of sacubitril/valsartan andCENTRAL ILLUSTRATION Continued
Heart failure (HF) stimulates both the renin-angiotensin system and the
moieties, the angiotensin receptor blocker valsartan and the neprilysin
angiotensin type I (AT1) receptor. Sacubitril is converted enzymatically to
enzyme that breaks down atrial natriuretic peptide (ANP), brain (or B-typ
as well as other vasoactive substances. N-terminal pro-BNP (NT-proBNP
Vardeny et al. (15) (mechanism of action panel).valsartan on relevant cardiac and renal biomarkers at
several time points, with samples collected before
study medication, after valsartan single-blind run-in,
after sacubitril/valsartan single-blind run-in, and at
16 and 48 weeks after randomization.
STUDY OBJECTIVES. The primary objective of this
study is to evaluate the efﬁcacy of sacubitril/
valsartan compared with valsartan in reducing the
rate of the composite endpoint of cardiovascular
death and total (ﬁrst and recurrent) HFHs. Secondary
objectives include comparing sacubitril/valsartan and
valsartan in: 1) improving the KCCQ clinical summary
score for HF symptoms and physical limitations at 8
months; 2) improving NYHA functional classiﬁcation
at 8 months; 3) delaying the time to ﬁrst occurrence of
either a $50% in estimated glomerular ﬁltration rate
relative to baseline, attainment of end-stage renal
disease, or renal death; and 4) delaying the time to
all-cause death. Exploratory objectives are listed
in Table 2.
Protocol amendments . The modiﬁcations imple-
mented in the 4 PARAGON-HF protocol amendments
to date are summarized in Online Table 2.
STUDY MANAGEMENT AND COMMITTEES. PARAGON-HF
is conducted by Novartis under the guidance and
leadership of an academic steering committee. An
independent external Data Monitoring Committee
(DMC) oversees the safety of the patients in the trial
and reviews the results of the interim efﬁcacy
analysis. An Endpoint Adjudication Committee is
responsible for classifying all deaths and adjudi-
cating all nonfatal events. A separate committee is
responsible for adjudicating suspected cases of
angioedema.
STATISTICAL CONSIDERATIONS. The primary efﬁ-
cacy variable is the cumulative number of primary
composite endpoint events, that is, the total number
of Endpoint Adjudication Committee–conﬁrmed
HFHs, as well as cardiovascular death, for each
subject over time. The analysis is based on a semi-
parametric proportional rates model (22), the LWYY
method, which is a modiﬁed Anderson and Gill modelnatriuretic peptide system. LCZ696 is composed of 2 molecular
inhibitor prodrug sacubitril (AHU377). Valsartan blocks the
the active neprilysin inhibitor LBQ657, which inhibits neprilysin, an
e) natriuretic peptide (BNP), and C-type natriuretic peptide (CNP),
) is not a substrate for neprilysin. Adapted with permission from
TABLE 2 Study Objectives
Primary objective
To compare sacubitril/valsartan to valsartan in reducing the rate of the composite
endpoint of cardiovascular death and total (ﬁrst and recurrent) HF
hospitalizations in HF patients (NYHA functional class II to IV) with preserved
EF (LVEF $45%)
Secondary objectives
To compare the effects of sacubitril/valsartan and valsartan on:
 Changes in the clinical summary score for HF symptoms and physical
limitations, as assessed by the KCCQ) at 8 months
 Improving NYHA functional classiﬁcation at 8 months
 Delaying the time to ﬁrst occurrence of a composite renal endpoint,
deﬁned as:
B Renal death, or
B Reaching end-stage renal disease (ESRD), or
B $50% decline in eGFR relative to baseline
 Delaying the time to all-cause mortality
Exploratory objectives
To compare the effects of sacubitril/valsartan and valsartan on:
 Reducing the rate of the composite endpoint of cardiovascular death,
total HF hospitalizations, total nonfatal strokes, and total nonfatal MIs
(total is deﬁned as the ﬁrst and all recurrent events)
 Changes in clinical composite assessment (assessed by NYHA functional
class, global patient assessment, and major adverse clinical events as
deﬁned by cardiovascular death and hospitalization for HF) at 8 months
 Patient global assessment at 8 months
 Reducing the rate of the composite endpoint of cardiovascular death,
total nonfatal HF hospitalizations, total nonfatal strokes, and total
nonfatal MIs (total is deﬁned as the ﬁrst and all recurrent events)
 Delaying the time to new-onset AF
 Changes in health-related quality of life (assessed by overall summary
score, clinical summary score, and individual scores of the subdomains
from the KCCQ [relative to treatment run-in epoch baseline scores and
relative to randomized treatment epoch baseline scores] and total score
of the EQ-5D for health status)
 Reducing cardiovascular deaths and total worsening HF events. A subject
will be deﬁned as having a cardiovascular death or worsening HF event
when the subject has:
B Cardiovascular death, or
B A hospitalization for HF, or
B Received IV decongestive therapy (IV diuretic agents, IV nesiritide or
other natriuretic peptide, IV inotropes, and IV nitroglycerin) that does
not result in formal inpatient hospital admission, regardless of the
setting (i.e., in an ED setting, in the physician’s ofﬁce, an outpatient
treatment facility, and so on)
 Hospitalizations (all cause and cause speciﬁc)
 The number of days alive and out of hospital at 12 months
 Slowing the rate of decline in eGFR
 Delaying time to new-onset diabetes mellitus
 Reducing healthcare resource utilization (e.g., number of days/stays in
intensive care unit, number of rehospitalizations, and number of ED visits
for HF)
 30-day HF hospital readmissions and readmission rate after a prior HF
hospitalization
 Time between HF hospital readmissions
 The proﬁle of pre-speciﬁed biomarkers (e.g., cardiac, vascular, renal,
collagen, metabolism, inﬂammatory, and/or other relevant biomarkers)
from baseline to pre-deﬁned time points in a subset of patients
 The primary composite and secondary endpoints, and key exploratory
endpoints in ACEI-intolerant patients
 Evaluating the changes in cognitive function (assessed by the MMSE)
at 2 yrs
 To characterize sacubitril/valsartan and valsartan PK at steady state using
population modeling and/or noncompartmental based methods in a
subset of patients
ED ¼ emergency department; EF ¼ ejection fraction; IV ¼ intravenous; KCCQ ¼ Kansas City
Cardiomyopathy Questionnaire; MMSE ¼ Mini Mental State Examination; PK ¼ pharmacokinetics;
other abbreviations as in Table 1.
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478(23) with a robust variance estimator to account for
the dependency of within-subject recurrent events,
with treatment group as a factor and stratiﬁed by
geographic region. As part of the primary analysis, thecomponents in the composite endpoint (total HFHs,
cardiovascular death) will also be analyzed separately
to quantify the respective treatment effects and
assess consistency. A joint gamma frailty model (24)
approach, which models total HFHs with the
Poisson regression model and cardiovascular death
with the exponential regression model and joins the
2 models through a gamma frailty, will be used for the
component analyses to address the potential bias of
cardiovascular death as a semicompeting risk and to
account for the correlation between HFH and
cardiovascular death.
Sample size and power were calculated through
simulations with the pseudo-data generated using
the parametric joint gamma frailty model. The control
group rate of total HFHs and cardiovascular death
rate were estimated in 2 steps. First, based on the
candesartan group of the CHARM-Preserved (Cande-
sartan in Heart Failure Assessment of Reduction in
Mortality and Morbidity-Preserved) study for patients
with LVEF $45%, the joint model, we estimated a
Poisson baseline intensity of 0.00032 HFHs per day
per patient and an exponential hazard rate of
0.000136 cardiovascular deaths per day per patient,
with the estimated gamma shape parameter of 0.193,
which resulted in annualized rates of 0.083 for time
to ﬁrst primary event and 0.036 for cardiovascular
mortality. We then increased these rates by 8% and
adjusted the corresponding Poisson intensity and
exponential hazard rates proportionally to annual-
ized rates of 0.09 and 0.04 for time to ﬁrst primary
event and cardiovascular death, respectively,
reﬂecting the requirement for elevated NPs, recent
HFHs, and imaging evidence of structural heart dis-
ease for enrollment. For various combinations of ef-
fect size scenarios and sample sizes, 3,000 studies
were simulated with uniform patient enrolment over
29 months and a minimum follow-up of 26 months,
and the primary analysis was performed using a
1-sided alpha level of 0.025. It was estimated that
4,600 patients would provide 95% power for the
primary analysis, assuming approximately 1,847 pri-
mary events had accrued, if the true primary
endpoint rate reduction were 22%, which approxi-
mately corresponds to a 30% reduction for total HFHs
and 10% for cardiovascular death, under the assumed
model. For a smaller reduction of 19% in the primary
endpoint rate, corresponding to a 25% reduction for
total HFHs and 10% for cardiovascular death, the
study would have 84% power for the primary
analysis.
For secondary endpoints, change from baseline in
KCCQ clinical summary score at 8 months will be
analyzed using a repeated-measures ANCOVA model,
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479together with the mixed-effect logistic responder
analyses for 5-point deterioration and 5-point
improvement; change from baseline in NYHA func-
tional class at 8 months will be analyzed using a
repeated-measures proportional cumulative odds
model; time to ﬁrst renal impairment composite
outcome and time to all-cause death will also be
analyzed with Cox proportional hazard models. The
multiplicity for the comparisons across the primary
and secondary endpoints will be adjusted on the basis
of a sequentially rejective multiple test procedure
(25). If the primary endpoint is statistically signiﬁcant
at the signiﬁcance-level alpha (e.g., 1-sided level of
0.024 at the end), then the KCCQ and NYHA
endpoints will be tested at level alpha/2. If one of
them is statistically signiﬁcant at this level, the other
can be tested at level alpha. If both KCCQ and NYHA
endpoints are statistically signiﬁcant, the composite
renal endpoint can be tested at level alpha. The
all-cause mortality endpoint will be tested at level
alpha, after the rejection of the primary hypothesis.
The endpoints for the exploratory objectives in
Table 2 will also be analyzed using appropriate
methods.
Study durat ion , inter im ana lyses , and ear ly
terminat ion . PARAGON-HF is an event-driven trial,
and all randomized patients will be followed up until
at least 1,847 total (ﬁrst and recurrent) HFHs and
cardiovascular deaths occur, with follow-up of $26
months after randomization for all noncensored pa-
tients to obtain the target power, unless the DMC
recommends that the study be stopped earlier for
efﬁcacy or safety reasons. The minimum follow-up
duration can be blindly re-estimated using the
power simulation model with the target power and
updated estimated model parameters based on the
data collected around the time of the efﬁcacy interim
analysis. The total trial length depends on the overall
duration of the patient recruitment period and the
time taken to accrue the pre-speciﬁed number of
primary events.
One interim efﬁcacy analysis is planned to assess
the primary endpoint when approximately two-thirds
of the target number of primary events have been
adjudicated, using a 1-sided alpha of 0.001. The study
can be stopped earlier in the interim analysis for
superiority only when both the primary endpoint and
cardiovascular death are statistically signiﬁcant at a
one-sided alpha of 0.001. The signiﬁcance level of
alpha to be used for the ﬁnal analysis will be adjusted
for the interim analysis to control the overall type I
error at 0.025 (1-sided). Interim safety analyses are
conducted by the DMC biannually.DISCUSSION
HFpEF is morbid and costly and accounts for a
growing proportion of patients with HF, yet current
therapy for HFpEF remains empiric. Neprilysin in-
hibition represents a potentially novel therapeutic
strategy, with promising experimental and phase II
mechanistic data. Four prior outcomes trials in
HFpEF that have focused on inhibiting the RAAS
with ACE inhibitors, ARBs, and mineralocorticoid
receptor antagonists have not been successful.
In contrast to prior HFpEF outcomes trials,
PARAGON-HF uses a novel therapy, was preceded by
a positive phase II trial, and was designed to address
many of the perceived shortcomings of these
prior trials.
We chose an active comparator, valsartan,
because RAAS inhibitors are widely used in HFpEF
patients, predominantly to treat comorbidities such
as hypertension (11,12). Because sacubitril/valsartan
cannot be administered in conjunction with an ACE
inhibitor because of the increased risk of angio-
edema, we standardized the active RAAS inhibitor
comparator arm in PARAGON-HF. The choice of
RAAS inhibitor, valsartan, differed from that used in
PARADIGM-HF (where the comparator was enalap-
ril) because, unlike in HFrEF, there is no standard
of care for RAAS inhibition in HFpEF. The target
dose of sacubitril/valsartan was based on the
PARADIGM-HF and PARAMOUNT trials and is the
dose that achieves similar systemic exposure as
160 mg bid of the valsartan international formula-
tion, as well as 90% of the maximum neprilysin
inhibition (16,21).
There has been concern that the failure of prior
trials in HFpEF might have been related to inclusion
criteria, as well as aspects of the trial design and
execution. Because the diagnosis of HF can be
difﬁcult when LVEF is preserved, it is likely that
some patients enrolled in prior HFpEF trials may
not have truly had HF, as was likely the case for
many patients enrolled from Russia and Georgia in
TOPCAT (Treatment of Preserved Cardiac Function
Heart Failure With an Aldosterone Antagonist) (26).
This issue remains a concern in all HFpEF trials,
and the possibility that misdiagnosis might have
played a role in the failure of other trials cannot be
ruled out. Other problems, such as dropout and
crossover, might have further compromised prior
HFpEF trials (10).
The inclusion criteria of PARAGON-HF were
designed to mitigate issues that might have been
problematic for prior HFpEF trials (Table 3). To ensure
TABLE 3 Comparison of PARAGON-HF and Prior HFpEF Trials
CHARM-P
(n ¼ 3,023)
PEP-CHF
(n ¼ 850)
I-PRESERVE
(n ¼ 4,128)
TOPCAT
(n ¼ 3,445)
PARAGON-HF
(n ¼ 4,800)
Treatment arms Candesartan vs.
placebo
Perindopril vs. placebo Irbesartan vs. placebo Spironolactone vs.
placebo
Sacubitril/valsartan vs. valsartan
Key inclusion
criteria
NYHA functional
class II to IV,
prior CVH
Clinical diagnosis of DHF
with signs/symptoms of
HF, $2 of the following:
LAE/LVH/impaired LV
ﬁlling/AF
NYHA functional class II-IV þ any
corroborating evidence
(e.g., HF sign), LVH or LAE
considered optional
corroborating evidence, HFH
required unless in NYHA
functional class III-IV
Yes. $1 HF
symptom þ $1 HF
sign, elevated NP,
or HFH
Yes. NYHA functional class II-IV,
elevated NT-proBNP. Mildly
elevated NT-proBNP if prior
HFH, structural heart disease
(LAE or LVH)
Endpoint First of either
CVD or HFH
First of either all-cause
death or HFH
First of either all-cause
death or CVH
First of either CVD,
HFH, or RSD
CVD and total HFH (ﬁrst and
recurrent)
CHARM-P ¼ Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity-Preserved; CVD ¼ cardiovascular disease; CVH ¼ cardiovascular hospitalization; DHF ¼ diastolic heart failure;
HFH ¼ heart failure hospitalization; HFpEF ¼ heart failure with preserved ejection fraction; I-PRESERVE ¼ Irbesartan in Heart Failure With Preserved Ejection Fraction; LAE ¼ left atrial enlargement; LV ¼ left
ventricular; NP ¼ natriuretic peptide; PARAGON-HF ¼ Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction; PEP-CHF ¼ Perindopril in Elderly People With
Chronic Heart Failure; RSD ¼ resuscitated sudden death; TOPCAT ¼ Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist; other abbreviations as in Table 1.
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480that patients enrolled had HF and that their signs and
symptoms were not simply due to other disease
states, all patients enrolled in PARAGON-HF after an
early protocol amendment were required to have mild
NP elevation, regardless of whether they were hos-
pitalized for HF in the recent past. This criterion was
designed to ensure that a patient would not be
enrolled solely on the basis of an HFH, which might
be difﬁcult to verify. Additionally, all patients in
PARAGON-HF were required to have structural heart
disease, some degree of LVH or LA enlargement, both
of which are known to be markers of risk in HFpEF
(27,28). These criteria were not speciﬁcally required
in all patients by prior HFpEF outcomes trials
(Table 3).
PARAGON-HF uses a novel primary endpoint,
reduction in ﬁrst and recurrent HFHs and cardio-
vascular death, with a recurrent event analysis
method. All prior HFpEF outcomes trials and most
trials in HF in general have used time-to-ﬁrst-event
analysis for the primary endpoint assessment. How-
ever, patients with HFpEF experience recurrent
hospitalizations, with each event contributing to the
patient’s burden and resource utilization. The use of
recurrent events, therefore, might allow for better
assessment of the true disease burden, and post hoc
reanalysis of total events in the CHARM-Preserved
trial (nearly double that of ﬁrst events) using
several recurrent event methods demonstrated sig-
niﬁcant reduction in hospitalizations in patients who
were given candesartan (29). PARAGON-HF will use
the LWYY semiparametric proportional rates model
approach to assess the primary endpoint, an
approach that has been vetted and accepted by reg-
ulatory authorities. This variation on the Andersen-
Gill (23) method uses a robust variance estimator
and makes no assumption of event independence.Prior modeling of this method using data from
CHARM-Preserved suggested that it would provide
an improvement in statistical power compared with
the conventional time-to-ﬁrst-event approach. Event
rate estimations were further informed after the
TOPCAT data became available.
Several substudies and exploratory endpoints will
complement the primary analyses. Echocardiography
assessment at screening will help characterize car-
diac structure and function in this population. A
cognitive function study using the Mini Mental State
Examination is being performed to explore the
theoretical risk that inhibition of neprilysin would
attenuate the breakdown of neurotoxic amyloid-beta
peptides in the brain and contribute to the risk of
impairment in cognitive function. There are
currently no human data supporting this risk with
sacubitril/valsartan (30), and data from PARADIGM-
HF did not demonstrate an increased risk of de-
mentia in patients treated with this drug (31).
Indeed, cognitive function might improve in the
sacubitril/valsartan group if the test treatment is
effective. Prevention of HFHs could be important,
because episodes of critical illness are associated
with marked cognitive decline over the subsequent
12 months (32). Similarly, improved cardiac function
and cerebral blood ﬂow in HF patients might
improve cognitive function.
STUDY LIMITATIONS. As with any clinical trial, the
design of PARAGON-HF has several limitations that
should be considered. The requirement for elevation
in NPs might exclude some patients with HFpEF
without such elevation. In addition, PARAGON-HF
excludes patients with body mass index >40 kg/m2
because of the difﬁculty of diagnosing HF in this
population. These exclusions could limit the
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481generalizability of the PARAGON-HF results in speciﬁc
populations. Moreover, PARAGON-HF uses an ejection
fraction cutoff for HFpEF that has been commonly
used in prior trials. More recently, the European
Society of Cardiology guidelines proposed a new
nomenclature categorizing HF patients in the LVEF
40% to 50% range “heart failure with mid-range
ejection fraction (HFmREF).” PARAGON-HF will
include patients in part but not all of this range.
CONCLUSIONS
PARAGON-HF will assess in patients with HFpEF
the beneﬁt of sacubitril/valsartan, a drug that hasbeen proven to reduce morbidity and mortality in
HFrEF and that has demonstrated efﬁcacy in a
phase II trial in patients with HFpEF. The design
of PARAGON-HF, the largest phase III HFpEF
trial to date, has considered several concerns
from prior neutral clinical trials in HFpEF and
has the potential to provide an evidenced-based
therapeutic option for patients with this syndrome.
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